Requested actions Be aware, on Feb. 22, Centers for Disease Control and Prevention (CDC) revised its COVID-19 vaccine clinical considerations. An 8-week interval between first and second doses of mRNA COVID-19 vaccine (Moderna and Pfizer) may be optimal for males 12–39 years old to reduce risk of myocarditis and increase efficacy. CDC still recommends a … 02/25/22 Health Advisory: COVID-19 Updates for Providers
COVID-19 Updates for Providers Requested actions Be aware, on February 11, the Centers for Disease Control and Prevention updated their guidance for COVID-19 vaccination to include: For people who are moderately or severely immunocompromised: People who have completed a primary series of an mRNA vaccine (Pfizer-BioNTech or Moderna) are recommended to receive an mRNA booster … 02/14/22 Health Advisory: CDC Updated Covid-19 Vaccination Guidelines; FDA Postponed its pediatric Covid-19 Vaccination Review
COVID-19 Updates for Providers Requested actions Be aware, U.S. Food and Drug Administration (FDA) granted full authorization to Moderna COVID-19 vaccine for people 18 years or older. Evidence shows the vaccine is safe and effective and manufactured with high quality. The vaccine will now be called Spikevax but has the same formulation as emergency use … 02/01/22 Health Advisory: FDA Provides Full Approval For Spikevax
COVID-19 Updates for Providers Requested actions Be aware, Centers for Disease Control and Prevention (CDC) endorsed Advisory Committee on Immunization Practices’ (ACIP’s) decision to strongly recommend a single Pfizer COVID-19 vaccine booster dose for people 12–17 years old at least 5 months after their primary series. This expands the age of booster access and strengthens … 01/06/22 Health Advisory: Booster Eligibility Expanded
COVID-19 Updates for Providers Requested actions Be aware, Centers for Disease Control and Prevention (CDC) updated its COVID-19 monoclonal antibody treatment recommendations. Sotrovimab monoclonal antibody formulation retains significant efficacy against Omicron, the dominant circulating variant. Other monoclonal antibody formulations under emergency use authorization (EUA)—bamlanivimab and etesevimab and casirivimab and imdevimab—lack clinical benefit against Omicron and … 01/04/22 Health Advisory: CDC updated antiviral guidance
COVID-19 Updates for Providers Requested actions Be aware, Food and Drug Administration (FDA) granted emergency use authorization (EUA) to the first oral antiviral treatment for COVID-19, Pfizer’s Paxlovid. The EUA comes after research showed Paxlovid was nearly 90% effective at preventing hospitalization and death in people 12 years or older at high risk of severe … 12/22/21 Health Advisory: Paxlovid granted EUA and Testing before gathering
COVID-19 Updates for Providers Requested actions Be aware, Centers for Disease Control and Prevention (CDC) and Western States Scientific Safety Review Workgroup recommend everyone 16 years or older get a COVID-19 vaccine booster dose at the recommended interval. This recommendation comes after Food and Drug Administration (FDA) expanded its emergency use authorization (EUA) for Pfizer-BioNTech … 12/13/21 Health Advisory: COVID-19 Updates for Providers
COVID-19 Updates for Providers Requested actions Be aware, Centers for Disease Control and Prevention (CDC) issued a health advisory warning of COVID-19 variant of concern Omicron (B.1.1.529). At least one case has been identified in the U.S.; it was linked to travel. Omicron has not been detected in Pierce County; however, we are tracking its … 12/03/21 Health Advisory: COVID-19 Updates for Providers
COVID-19 Updates for Providers Requested actions Be aware, following the Food and Drug Administration’s (FDA’s) decision to update its emergency use authorizations (EUAs) to allow COVID-19 vaccine booster doses for everyone 18 years or older, Centers for Disease Control and Prevention (CDC) and Western States Scientific Safety Review Workgroup recommend: People 50 years or older … 11/23/21 Health Advisory: COVID-19 vaccine booster doses available to everyone 18 years or older
To report a confirmed or suspect case of pertussis, complete the or call . Overview Pertussis is common and very contagious. It is caused by Bordetella pertussis. The bacteria infect cilia in the upper respiratory tract. Early symptoms are mild, like the common cold. Patients often experience violent coughing fits (paroxysms). These can be followed by … Pertussis Fact Sheet
